Unknown

Dataset Information

0

Targeted Integration and High-Level Transgene Expression in AAVS1 Transgenic Mice after In Vivo HSC Transduction with HDAd5/35++ Vectors.


ABSTRACT: Our goal is the development of in vivo hematopoietic stem cell (HSC) transduction technology with targeted integration. To achieve this, we modified helper-dependent HDAd5/35++ vectors to express a CRISPR/Cas9 specific to the "safe harbor" adeno-associated virus integration site 1 (AAVS1) locus and to provide a donor template for targeted integration through homology-dependent repair. We tested the HDAd-CRISPR + HDAd-donor vector system in AAVS1 transgenic mice using a standard ex vivo HSC gene therapy approach as well as a new in vivo HSC transduction approach that involves HSC mobilization and intravenous HDAd5/35++ injections. In both settings, the majority of treated mice had transgenes (GFP or human ?-globin) integrated into the AAVS1 locus. On average, >60% of peripheral blood cells expressed the transgene after in vivo selection with low-dose O6BG/bis-chloroethylnitrosourea (BCNU). Ex vivo and in vivo HSC transduction and selection studies with HDAd-CRISPR + HDAd-globin-donor resulted in stable ?-globin expression at levels that were significantly higher (>20% ?-globin of adult mouse globin) than those achieved in previous studies with a SB100x-transposase-based HDAd5/35++ system that mediates random integration. The ability to achieve therapeutically relevant transgene expression levels after in vivo HSC transduction and selection and targeted integration make our HDAd5/35++-based vector system a new tool in HSC gene therapy.

SUBMITTER: Li C 

PROVIDER: S-EPMC6904827 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Targeted Integration and High-Level Transgene Expression in AAVS1 Transgenic Mice after In Vivo HSC Transduction with HDAd5/35++ Vectors.

Li Chang C   Mishra Arpit Suresh AS   Gil Sucheol S   Wang Meng M   Georgakopoulou Aphrodite A   Papayannopoulou Thalia T   Hawkins R David RD   Lieber André A  

Molecular therapy : the journal of the American Society of Gene Therapy 20190819 12


Our goal is the development of in vivo hematopoietic stem cell (HSC) transduction technology with targeted integration. To achieve this, we modified helper-dependent HDAd5/35++ vectors to express a CRISPR/Cas9 specific to the "safe harbor" adeno-associated virus integration site 1 (AAVS1) locus and to provide a donor template for targeted integration through homology-dependent repair. We tested the HDAd-CRISPR + HDAd-donor vector system in AAVS1 transgenic mice using a standard ex vivo HSC gene  ...[more]

Similar Datasets

| S-EPMC2575058 | biostudies-literature
| S-EPMC5416772 | biostudies-literature
| S-EPMC10480530 | biostudies-literature
| S-EPMC3464636 | biostudies-literature
| S-EPMC3799456 | biostudies-other
| S-EPMC3899822 | biostudies-literature
| S-EPMC3503979 | biostudies-literature
| S-EPMC9020256 | biostudies-literature
| S-EPMC6744886 | biostudies-literature
| S-EPMC8741415 | biostudies-literature